Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2-9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of...
Saved in:
Main Authors: | Anita Bakrania (Author), Gang Zheng (Author), Mamatha Bhat (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanomedicine: a frontier of the breast cancer treatment
by: Swarup Sonar, et al.
Published: (2024) -
Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases
by: Anita Bakrania, et al.
Published: (2023) -
Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy
by: Lei Ding, et al.
Published: (2022) -
Exosome‐based therapy and targeted PROTAC delivery: A new nanomedicine frontier for HPV‐mediated cervical cancer treatment
by: Nobendu Mukerjee, et al.
Published: (2024) -
Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma
by: Lai Wei, et al.
Published: (2022)